GlassScriptPhysician profile
Carly Hornis
NPI 1073999769
$3,179.35
in general payments reported to CMS, 2019-2025
29 companies · $536 in 2025
The $536 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.37 · 2020: $205 · 2021: $528 · 2022: $578 · 2023: $680 · 2024: $612 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $548.13 | 2020-2025 | |
| Astellas Pharma US INC | $368.48 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $310.75 | 2021-2024 | |
| Pfizer INC. | $245.48 | 2019-2025 | |
| Biogen, INC. | $236.60 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $178.82 | 2021-2024 | Slynd |
| Novo Nordisk INC | $156.56 | 2020-2024 | Wegovy |
| Organon LLC | $149.01 | 2021-2025 | Jada System |
| Agile Therapeutics, INC. | $118.33 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $107.26 | 2020-2022 | |
| Amgen INC. | $95.45 | 2021-2023 | Evenity, Prolia |
| Shield Therapeutics INC | $79.62 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $63.84 | 2024-2025 | Myfembree, Gemtesa |
| Exact Sciences Corporation | $60.99 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $54.31 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $53.43 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $50.51 | 2019-2024 | Aptima |
| Meditrina | $44.12 | 2021 | |
| Coopersurgical, INC. | $41.67 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Lilly USA, LLC | $28.54 | 2025 | Zepbound |
| Radius Health, INC. | $27.60 | 2019-2020 | |
| Roche Diagnostics Corporation | $25.27 | 2020 | |
| Ascend Therapeutics US, LLC | $24.91 | 2024 | |
| Amag Pharmaceuticals, INC. | $23.32 | 2020 | |
| Evofem Biosciences, INC. | $19.71 | 2021 | |
| Lupin INC. | $19.44 | 2021 | |
| Avion Pharmaceuticals | $16.27 | 2020 | |
| Axonics, INC. | $16.00 | 2024 | Bulkamid, Axonics |
| Medicem INC. | $14.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Hornis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.